Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: Retrospective analysis of a prospective clinical trial in Zimbabwe

International Journal of Infectious Diseases

Volumn 24, Issue , 2014, Pages 6-10

  Erlandson, Kristine M ^a   Gudza, Ivy ^b   Fiorillo, Suzanne ^a   Ndemera, Buxton ^b   Schooley, Robert T ^c   Gwanzura, Lovemore ^b   Borok, Margaret ^b   Campbell, Thomas B ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

AIDS KS; HIV; Vitamin D insufficiency

Indexed keywords

25 HYDROXYVITAMIN D; ABACAVIR PLUS LAMIVUDINE; VIRUS RNA; VITAMIN D; ZIDOVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 25-HYDROXYVITAMIN D; ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CHEMOTHERAPY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE; VIRUS LOAD; VITAMIN D DEFICIENCY; ZIMBABWE; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN HERPESVIRUS 8; MIDDLE AGED; MORTALITY; PATHOLOGY; PILOT STUDY; PROSPECTIVE STUDY; RISK; SARCOMA, KAPOSI; SURVIVAL; TREATMENT OUTCOME; VIROLOGY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DISEASE PROGRESSION; FEMALE; HERPESVIRUS 8, HUMAN; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ODDS RATIO; PILOT PROJECTS; PROSPECTIVE STUDIES; RNA, VIRAL; SARCOMA, KAPOSI; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; ZIDOVUDINE; ZIMBABWE;

EID: 84900427876     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.02.006     Document Type: Article

References (49)

1. Chokunonga E., Levy L.M., Bassett M.T., Mauchaza B.G., Thomas D.B., Parkin D.M. Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993-1995. Int J Cancer 2000, 85:54-59.
2. Olweny C.L., Borok M., Gudza I., Clinch J., Cheang M., Kiire C.F., et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer 2005, 113:632-639.
3. Borok M., Fiorillo S., Gudza I., Putnam B., Ndemera B., White I.E., et al. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin Infect Dis 2010, 51:342-349.
4. Giovannucci E. Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 2009, 19:84-88.
5. Mizoue T., Kimura Y., Toyomura K., Nagano J., Kono S., Mibu R., et al. Calcium, dairy foods, vitamin D, and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. Cancer Epidemiol Biomarkers Prev 2008, 17:2800-2807.
6. Schwartz G.G. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol 2009, 19:96-102.
7. John E.M., Schwartz G.G., Dreon D.M., Koo J. Vitamin D and breast cancer risk: the NHANES I epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 1999, 8:399-406.
8. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006, 98:451-459.
9. Ben-Shoshan M., Amir S., Dang D.T., Dang L.H., Weisman Y., Mabjeesh N.J. 1alpha, 25-dihydroxyvitamin D3 (calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 2007, 6:1433-1439.
10. Gruber H.E., Hoelscher G., Ingram J.A., Chow Y., Loeffler B., Hanley E.N. 1,25(OH)2-vitamin D3 inhibits proliferation and decreases production of monocyte chemoattractant protein-1, thrombopoietin, VEGF, and angiogenin by human annulus cells in vitro. Spine 2008, 33:755-765.
11. Chung I., Han G., Seshadri M., Gillard B.M., Yu W.D., Foster B.A., et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 2009, 69:967-975.
12. Cardus A., Panizo S., Encinas M., Dolcet X., Gallego C., Aldea M., et al. 1,25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009, 204:85-89.
13. Grant W.B. Role of vitamin D in up-regulating VEGF and reducing the risk of pre-eclampsia. Clin Sci (Lond) 2009, 116:871.
14. Masood R., Nagpal S., Zheng T., Cai J., Tulpule A., Smith D.L., et al. Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood 2000, 96:3188-3194.
15. Gonzalez-Pardo V., Verstuyf A., Boland R., Russo de Boland A. Vitamin D analogue TX 527 down-regulates the NF-kappaB pathway and controls the proliferation of endothelial cells transformed by Kaposi sarcoma herpesvirus. Br J Pharmacol 2013, 169:1635-1645.
16. Gonzalez-Pardo V., Suares A., Verstuyf A., De Clercq P., Boland R., Boland A.R. Cell cycle arrest and apoptosis induced by 1alpha, 25(OH)D and TX 527 in Kaposi sarcoma is VDR dependent. J Steroid Biochem Mol Biol 2013 Dec 5, [Epub ahead of print].
17. Gonzalez-Pardo V., Martin D., Gutkind J.S., Verstuyf A., Bouillon R., de Boland A.R., et al. 1 Alpha, 25-dihydroxyvitamin D3 and its TX527 analog inhibit the growth of endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein-coupled receptor in vitro and in vivo. Endocrinology 2010, 151:23-31.
18. Gonzalez-Pardo V., D'Elia N., Verstuyf A., Boland R., Russo de Boland A. NFkappaB pathway is down-regulated by 1alpha, 25(OH)(2)-vitamin D(3) in endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein coupled receptor. Steroids 2012, 77:1025-1032.
19. Kim J.H., Gandhi V., Psevdos G., Espinoza F., Park J., Sharp V. Evaluation of vitamin D levels among HIV-infected patients in New York City. AIDS Res Hum Retroviruses 2012, 28:235-241.
20. Dao C.N., Patel P., Overton E.T., Rhame F., Pals S.L., Johnson C., et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011, 52:396-405.
21. Overton E.T., Yin M.T. The rapidly evolving research on vitamin D among HIV-infected populations. Curr Infect Dis Rep 2011, 13:83-93.
22. Viard J.P., Souberbielle J.C., Kirk O., Reekie J., Knysz B., Losso M., et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 2011, 25:1305-1315.
23. Gibney K.B., Mihrshahi S., Torresi J., Marshall C., Leder K., Biggs B.A. The profile of health problems in African immigrants attending an infectious disease unit in Melbourne, Australia. Am J Trop Med Hyg 2009, 80:805-811.
24. Woolley I.J., Giles M.L., Howard J.E., Korman T.M. Unrecognised vitamin D deficiency: low concentrations in African migrants with HIV in Australia. Sex Health 2008, 5:375-376.
25. van der Meer I.M., Middelkoop B.J., Boeke A.J., Lips P. Prevalence of vitamin D deficiency among Turkish, Moroccan, Indian and Sub-Sahara African populations in Europe and their countries of origin: an overview. Osteoporos Int 2011, 22:1009-1021.
26. Huntington M.K., Shafer C.W., Pudwill R., Boer L., Kendall J. Prevalence of vitamin D deficiency among immigrants to South Dakota. S D Med 2010, 63:51-55.
27. Vescini F., Cozzi-Lepri A., Borderi M., Re M.C., Maggiolo F., De Luca A., et al. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr 2011, 58:163-172.
28. Njemini R., Meyers I., Demanet C., Smitz J., Sosso M., Mets T. The prevalence of autoantibodies in an elderly Sub-Saharan African population. Clin Exp Immunol 2002, 127:99-106.
29. Friis H., Range N., Pedersen M.L., Molgaard C., Changalucha J., Krarup H., et al. Hypovitaminosis D is common among pulmonary tuberculosis patients in Tanzania but is not explained by the acute phase response. J Nutr 2008, 138:2474-2480.
30. Aspray T.J., Yan L., Prentice A. Parathyroid hormone and rates of bone formation are raised in perimenopausal rural Gambian women. Bone 2005, 36:710-720.
31. Glew R.H., Crossey M.J., Polanams J., Okolie H.I., VanderJagt D.J. Vitamin D status of seminomadic Fulani men and women. J Natl Med Assoc 2010, 102:485-490.
32. Wejse C., Olesen R., Rabna P., Kaestel P., Gustafson P., Aaby P., et al. Serum 25-hydroxyvitamin D in a West African population of tuberculosis patients and unmatched healthy controls. Am J Clin Nutr 2007, 86:1376-1383.
33. Krigel R.L., Laubenstein L.J., Muggia F.M. Kaposi's sarcoma: a new staging classification. Cancer Treat Rep 1983, 67:531-534.
34. Krown S.E., Testa M.A., Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997, 15:3085-3092.
35. White I.E., Campbell T.B. Quantitation of cell-free and cell-associated Kaposi's sarcoma-associated herpesvirus DNA by real-time PCR. J Clin Microbiol 2000, 38:1992-1995.
36. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
37. Holick M.F. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009, 19:73-78.
38. Campbell G.R., Spector S.A. Hormonally active vitamin D3 (1alpha, 25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection. J Biol Chem 2011, 286:18890-18902.
39. Locardi C., Petrini C., Boccoli G., Testa U., Dieffenbach C., Butto S., et al. Increased human immunodeficiency virus (HIV) expression in chronically infected U937 cells upon in vitro differentiation by hydroxyvitamin D3: roles of interferon and tumor necrosis factor in regulation of HIV production. J Virol 1990, 64:5874-5882.
40. Pauza C.D., Kornbluth R., Emau P., Richman D.D., Deftos L.J. Vitamin D3 compounds regulate human immunodeficiency virus type 1 replication in U937 monoblastoid cells and in monocyte-derived macrophages. J Leukoc Biol 1993, 53:157-164.
41. Bearden A., Abad C., Gangnon R., Sosman J.M., Binkley N., Safdar N. Cross-sectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults. J Clin Endocrinol Metab 2013, 98:1726-1733.
42. Goletti D., Kinter A.L., Biswas P., Bende S.M., Poli G., Fauci A.S. Effect of cellular differentiation on cytokine-induced expression of human immunodeficiency virus in chronically infected promonocytic cells: dissociation of cellular differentiation and viral expression. J Virol 1995, 69:2540-2546.
43. Campbell G.R., Spector S.A. Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog 2012, 8:e1002689.
44. Haug C.J., Aukrust P., Haug E., Morkrid L., Muller F., Froland S.S. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 1998, 83:3832-3838.
45. Villamor E. A potential role for vitamin D on HIV infection?. Nutr Rev 2006, 64:226-233.
46. Mehta S., Hunter D.J., Mugusi F.M., Spiegelman D., Manji K.P., Giovannucci E.L., et al. Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. J Infect Dis 2009, 200:1022-1030.
47. Tostmann A., Wielders J.P., Kibiki G.S., Verhoef H., Boeree M.J., van der Ven A.J. Serum 25-hydroxy-vitamin D3 concentrations increase during tuberculosis treatment in Tanzania. Int J Tuberc Lung Dis 2010, 14:1147-1152.
48. Mehta S., Giovannucci E., Mugusi F.M., Spiegelman D., Aboud S., Hertzmark E., et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One 2010, 5:e8770.
49. Ross A.C., Judd S., Kumari M., Hileman C., Storer N., Labbato D., et al. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther 2011, 16:555-563.